Thirty percent of the current veteran population is suffering from some level of post traumatic stress, according to VA statistics. Treatments vary, but researchers and doctors are aggressively responding to the crisis.
As marijuana begins to gain traction in treating veteran PTS (the Veterans Administration maintains its position that marijuana has only an "anecdotal effect" on veteran post-traumatic stress) researchers are examining other recreational drugs to treating the unseen wounds of war. And the newest drug under scrutiny is methylene-dioxy-meth-amphetamine, better known as "MDMA," "Molly," or "ecstasy."
Pure MDMA is of interest to neuroscientists because of its effect on human empathy, fear, and defensiveness. In a recent Popular Science article, psychiatrist Dr. Michael Mithoefer said that 83 percent of his treatment resistant patients not only responded positively to MDMA treatment, they soon showed no symptoms at all.
Other reports show the drug works in treating end-of-life anxiety and alcoholism. Rick Doblin, who runs the nonprofit Multidisciplinary Association for Psychedelic Studies, thinks the FDA could allow the use of MDMA as a viable treatment option as early as 2021.
In studies published by the U.S. National Library of Medicine National Institutes of Health, MDMA was found to be addictive in "rare cases." One being a veteran self-medicating with MDMA to treat his own post-traumatic stress. Clearly, more study is needed.